PFE - Roivant Sciences has reportedly drawn $7B+ interest in bowel drug
2023-07-06 14:55:08 ET
- Shares of U.K.-based biotech Roivant Sciences ( NASDAQ: ROIV ) reached a session high on Thursday triggering a trading halt after Bloomberg reported that the company has attracted biopharma interest in $7B bowel drug.
- Accordig to the report, large biopharma firms are said to be studying the acquisition of Roivant’s ( ROIV ) anti-TL1A antibody.
- Roivant’s ( ROIV ) pipeline includes anti-TL1A agent RVT-3101 for which the company partnered with Pfizer ( PFE ) to develop it for ulcerative colitis and other inflammatory/ fibrotic diseases through a subsidiary called Vant.
- Per the terms, Pfizer ( PFE ) will represent Vant board and keep commercial rights for RVT-3101 outside the U.S. and Japan.
- Vant will fund the development of RVT-3101 and hold commercial rights for the treatment in the U.S. and Japan.
For further details see:
Roivant Sciences has reportedly drawn $7B+ interest in bowel drug